Acne Vulgaris - Pipeline Review, H1 2016

Description: Acne Vulgaris - Pipeline Review, H1 2016

Summary

‘Acne Vulgaris - Pipeline Review, H1 2016’, provides an overview of the Acne Vulgaris pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acne Vulgaris, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acne Vulgaris and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acne Vulgaris
- The report reviews pipeline therapeutics for Acne Vulgaris by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Acne Vulgaris therapeutics and enlists all their major and minor projects
- The report assesses Acne Vulgaris therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Acne Vulgaris

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Acne Vulgaris
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acne Vulgaris pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:

List of Tables
List of Figures
Introduction
Report Coverage
Acne Vulgaris Overview
Therapeutics Development
Pipeline Products for Acne Vulgaris - Overview
Pipeline Products for Acne Vulgaris - Comparative Analysis
Acne Vulgaris - Therapeutics under Development by Companies
Acne Vulgaris - Therapeutics under Investigation by Universities/Institutes
Acne Vulgaris - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Acne Vulgaris - Products under Development by Companies
Acne Vulgaris - Products under Investigation by Universities/Institutes
Acne Vulgaris - Companies Involved in Therapeutics Development
3SBio Inc.
Ache Laboratorios Farmaceuticos S/A
Allergan Plc
Almirall, S.A.
Biomar Microbial Technologies
Braintree Laboratories, Inc.
Brickell Biotech, Inc.
Celtaxisys, Inc.
Delenex Therapeutics AG
DermaXon, LLC
Dermira Inc.
Diffusion Pharmaceuticals Inc.
ELORAC, Inc.
Ensol Biosciences Inc.
Foamix Pharmaceuticals Ltd.
Galderma S.A.
GlaxoSmithKline Plc
Helix BioMedix, Inc.
Hovione FarmaCiencia SA
Lee's Pharmaceutical Holdings Limited
Novabiotics Limited
Novan, Inc.
Paratek Pharmaceuticals, Inc.
Phosphagenics Limited
Photocure ASA
Promius Pharma, LLC
Provectus Biopharmaceuticals, Inc.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
SkyePharma Plc
Sol-Gel Technologies Ltd.
Telesso Technologies Limited
Thesan Pharmaceuticals, Inc.
Valeant Pharmaceuticals International, Inc.
Venn Life Sciences Holdings Plc
Vyome Biosciences Private Limited
XBiotech USA, Inc.
Xenon Pharmaceuticals Inc.
Acne Vulgaris - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type

Drug Profiles

(adapalene + benzoyl peroxide) - Drug Profile
(adapalene + benzoyl peroxide) - Drug Profile
(adapalene + clindamycin hydrochloride) - Drug Profile
(benzoyl peroxide + tretinoin) - Drug Profile
(clindamycin phosphate + tretinoin) - Drug Profile
A-3APO - Drug Profile
acebilustat - Drug Profile
Aczone X - Drug Profile
AD-037 - Drug Profile
aminolevulinic acid hydrochloride - Drug Profile
ANT-1207 - Drug Profile
AQ-401 - Drug Profile
ATx-202 - Drug Profile
B-244 - Drug Profile
BBI-3000 - Drug Profile
benzoyl peroxide - Drug Profile
BLI-1100 - Drug Profile
CB-0301 - Drug Profile
DFD-10 - Drug Profile
DLX-2323 - Drug Profile
DLX-2681 - Drug Profile
DMT-210 - Drug Profile
DRM-01 - Drug Profile
Drugs for Acne - Drug Profile
DX-0385 - Drug Profile
DX-0386 - Drug Profile
E-10215 - Drug Profile
finasteride - Drug Profile
FMX-101 - Drug Profile
GSK-1940029 - Drug Profile
HB-1345 - Drug Profile
Hesed-4000 - Drug Profile
IB-07A037 - Drug Profile
IDP-120 - Drug Profile
IDP-121 - Drug Profile
IDP-123 - Drug Profile
IDP-126 - Drug Profile
IDP-129 - Drug Profile
IDP-130 - Drug Profile
methyl aminolevulinate hydrochloride - Drug Profile
minocycline - Drug Profile
minocycline - Drug Profile
MTC-896 - Drug Profile
NAI-003 - Drug Profile
omiganan pentahydrochloride - Drug Profile
Peptide to Disrupt Bacterial Cell Membrane and Cell Wall for Acne And Skin Cancer - Drug Profile
PH-10 - Drug Profile
RA-18C3 - Drug Profile
RES-440 - Drug Profile
sarecycline hydrochloride - Drug Profile
SB-204 - Drug Profile
SKP-026 - Drug Profile
Small Molecule for Acne and Skin Inflammation - Drug Profile
SYN-1113 - Drug Profile
Synthetic Peptide for Acne Vulgaris - Drug Profile
Synthetic Peptides to Inhibit Kallikrein for Immunology, Dermatological and Genetic Disorders - Drug Profile
tretinoin - Drug Profile
trifarotene - Drug Profile
Vaccine for Acne Vulgaris - Drug Profile
VB-1953 - Drug Profile
XEN-801 - Drug Profile
Acne Vulgaris - Recent Pipeline Updates
Acne Vulgaris - Dormant Projects
Acne Vulgaris - Discontinued Products
Acne Vulgaris - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Acne Vulgaris, H1 2016
Number of Products under Development for Acne Vulgaris - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Development by Companies, H1 2016 (Contd..1)
Number of Products under Development by Companies, H1 2016 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016 (Contd..1)
Products under Development by Companies, H1 2016 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2016
Acne Vulgaris - Pipeline by 3SBio Inc., H1 2016
Acne Vulgaris - Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2016
Acne Vulgaris - Pipeline by Allergan Plc, H1 2016
Acne Vulgaris - Pipeline by Almirall, S.A., H1 2016
Acne Vulgaris - Pipeline by Biomar Microbial Technologies, H1 2016
Acne Vulgaris - Pipeline by Braintree Laboratories, Inc., H1 2016
Acne Vulgaris - Pipeline by Brickell Biotech, Inc., H1 2016
Acne Vulgaris - Pipeline by Celtaxsys, Inc., H1 2016
Acne Vulgaris - Pipeline by Delenex Therapeutics AG, H1 2016
Acne Vulgaris - Pipeline by DermaXon, LLC, H1 2016
Acne Vulgaris - Pipeline by Dermira Inc., H1 2016
Acne Vulgaris - Pipeline by Diffusion Pharmaceuticals Inc., H1 2016
Acne Vulgaris - Pipeline by ELORAC, Inc., H1 2016
Acne Vulgaris - Pipeline by Ensol Biosciences Inc., H1 2016
Acne Vulgaris - Pipeline by Foamix Pharmaceuticals Ltd., H1 2016
Acne Vulgaris - Pipeline by Galderma S.A., H1 2016
Acne Vulgaris - Pipeline by GlaxoSmithKline Plc, H1 2016
Acne Vulgaris - Pipeline by Helix BioMedix, Inc., H1 2016
Acne Vulgaris - Pipeline by Hovione FarmaCiencia SA, H1 2016
Acne Vulgaris - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2016
Acne Vulgaris - Pipeline by Novabiotics Limited, H1 2016
Acne Vulgaris - Pipeline by Novan, Inc., H1 2016
Acne Vulgaris - Pipeline by Paratek Pharmaceuticals, Inc., H1 2016
Acne Vulgaris - Pipeline by Phosphagenics Limited, H1 2016
Acne Vulgaris - Pipeline by Photocure ASA, H1 2016
Acne Vulgaris - Pipeline by Promius Pharma, LLC, H1 2016
Acne Vulgaris - Pipeline by Provectus Biopharmaceuticals, Inc., H1 2016
Acne Vulgaris - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H1 2016
Acne Vulgaris - Pipeline by SkyePharma Plc, H1 2016
Acne Vulgaris - Pipeline by Sol-Gel Technologies Ltd., H1 2016
Acne Vulgaris - Pipeline by Telesso Technologies Limited, H1 2016
Acne Vulgaris - Pipeline by Thesan Pharmaceuticals, Inc., H1 2016
Acne Vulgaris - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2016
Acne Vulgaris - Pipeline by Venn Life Sciences Holdings Plc, H1 2016
Acne Vulgaris - Pipeline by Vyome Biosciences Private Limited, H1 2016
Acne Vulgaris - Pipeline by XBiotech USA, Inc., H1 2016
Acne Vulgaris - Pipeline by Xenon Pharmaceuticals Inc., H1 2016
Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Acne Vulgaris Therapeutics - Recent Pipeline Updates, H1 2016
Acne Vulgaris - Dormant Projects, H1 2016
Acne Vulgaris - Dormant Projects (Contd..1), H1 2016
Acne Vulgaris - Dormant Projects (Contd..2), H1 2016
Acne Vulgaris - Dormant Projects (Contd..3), H1 2016
Acne Vulgaris - Dormant Projects (Contd..4), H1 2016
Acne Vulgaris - Dormant Projects (Contd..5), H1 2016
Acne Vulgaris - Dormant Projects (Contd..6), H1 2016
Acne Vulgaris - Discontinued Products, H1 2016
List of Figures
Number of Products under Development for Acne Vulgaris, H1 2016
Number of Products under Development for Acne Vulgaris - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Top 10 Targets, H1 2016
Number of Products by Stage and Top 10 Targets, H1 2016
Number of Products by Top 10 Mechanism of Actions, H1 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Types, H1 2016

Ordering:

Order Online - [http://www.researchandmarkets.com/reports/3734742/](http://www.researchandmarkets.com/reports/3734742/)

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Acne Vulgaris - Pipeline Review, H1 2016
Web Address: http://www.researchandmarkets.com/reports/3734742/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: ______________________  Mr  Mrs  Dr  Miss  Ms  Prof  _______
First Name: __________________________  Last Name: __________________________
Email Address: * __________________________
Job Title: __________________________
Organisation: __________________________
Address: __________________________
City: __________________________
Postal / Zip Code: __________________________
Country: __________________________
Phone Number: __________________________
Fax Number: __________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: 

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp